Although anti-psoriasis biologic agents inhibiting TNF-a, IL-23/IL-12, IL-17A, and IL-17 receptors have achieved great therapeutic effectiveness compared to traditional treatments, the therapeutic effects are varied between patients and the skin lesions often recur once the biologics will be withdrawn (61). The gene discussed is IL17A; the disease is psoriasis.